PHARMACOKINETICALLY DETERMINED CYCLOSPORINE DOSAGE IN YOUNG-CHILDREN

被引:64
作者
HOPPU, K
KOSKIMIES, O
HOLMBERG, C
HIRVISALO, EL
机构
[1] children's Hospital, University of Helsinki, Helsinki
[2] Department of Clinical Pharmacology, Karolinska Hospital, Stockholm
[3] Department of Clinical Pharmacology, University of Helsinki, Helsinki
关键词
CYCLOSPORINE; PHARMACOKINETICS; DOSING;
D O I
10.1007/BF00852828
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
To account for the individual variability in cyclosporine pharmacokinetics and the non-existence of dosing recommendations in young children, we studied the pharmacokinetics of cyclosporine before renal transplantation in ten children aged 1.1-2.5 years, to determine the appropriate individual dose. Our aim was to reach a steady-state cyclosporine blood level of 200-300-mu-g/l, 8 h after a dose in the first days after renal transplantation. Cyclosporine was given as a single oral dose (10 mg/kg) or as a 4-h i.v. infusion (3 mg/kg), and the blood concentration was determined for 24 h by a specific monoclonal radioimmunoassay. The mean terminal cyclosporine half-life (t1/2) was 9.3 h (range 2.8-20.4), blood clearance 10.8 ml/min per kilogram (range 6.8-22.7) and volume of distribution 2.8 l/kg (range 1.4-4.7). The bioavailability of oral cyclosporine was low; the mean amount absorbed was 21.8% of the administered dose (range 11-35). The mean calculated dose needed to attain the intended predose blood cyclosporine level of 200-300-mu-g/l at steady-state was 5 mg/kg per day for i.v. and 21 mg/kg per day for oral administration. In view of the short t1/2, we used three doses/day. The validity of the predicted doses is shown by the mean cyclosporine doses used during the first 10 days after transplantation, which were 93.5% of the calculated oral and 96.6% of the calculated i.v. doses. The observed mean cyclosporine concentration during the same period was 196-mu-g/l.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 13 条
[1]  
Yee G.C., Lennon T.P., Gmur D.J., Kennedy, Deeg H.J., Age-dependent cyclosporin: pharmacokinetics in marrow transplant recipients, Clin Pharmacol Ther, 40, pp. 438-443, (1986)
[2]  
Ptachcinski R.J., Burckart G.J., rosenthal J.T., Venkataramanan R., Howrie D.L., Taylor R.J., Avner E.D., Ellis D., Hakala T.R., Cyclosporin pharmacokinetics in children following cadaveric renal transplantation, Transplant Proc, 18, pp. 766-767, (1986)
[3]  
Morse G.D., Holdsworth M.T., Venuto R.C., Gerbasi J., Walshe J.J., Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period, Clin Pharmacol Ther, 44, pp. 654-664, (1988)
[4]  
Lokiec F., Fischer A., cluckman E., A safer approach to the clinical use of cyclosporine: the predose calculation, Transplant Proc, 18, pp. 194-199, (1986)
[5]  
Clardy C.W., Schroeder T.J., Myre S.A., Wadhwa N.K., Pesce A.J., First, McEnery P.T., Balisteri W.F., Harris R.E., Melvin D.B., Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants, Clin Chem, 34, pp. 2012-2015, (1988)
[6]  
Holmberg C., Jalanko H., Koskimies O., Leijala M., Salmela K., Eklund B., Wikstrom S., Ahonen J., Renal transplantation in children with congenital nephrotic syndrome of the Finnish type, Transplant Proc, 22, pp. 158-159, (1990)
[7]  
Wallemacq P.E., Lesne M., A new automated HPLC analysis of cyclosporin A and G in human serum, Journal of Chromatography B: Biomedical Sciences and Applications, 413, pp. 131-140, (1987)
[8]  
Gibaldi M., Biopharmaceutics and clinical pharmacokinetics, (1984)
[9]  
Ptachcinski R.J., Venkataramanan R., Burckart G.J., Clinical pharmacokinetics of cyclosporin, Clin Pharmacokinet, 11, pp. 107-132, (1986)
[10]  
Reynolds K.L., Grevel J., Gibbons S.Y., Welsh, Rutzky L.P., Kahan B.D., cyclosporine pharmacokinetics in uremic patients: influence of different assay methods, Transplant Proc, 20, pp. 462-465, (1988)